Global Cancer Monoclonal Antibodies Market Size (2024 - 2029)

The cancer monoclonal antibodies market is poised for growth, driven by factors such as the increasing prevalence of cancer, advancements in genomic research, and the specificity of monoclonal antibodies in targeting cancer cells. The market's expansion is further supported by strategic initiatives from key players, despite the challenges posed by rigorous regulatory processes. The COVID-19 pandemic has also influenced the market dynamics, highlighting the broader applications of monoclonal antibodies.

Market Size of Global Cancer Monoclonal Antibodies Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Cancer Monoclonal Antibodies Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 9.20 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Cancer Monoclonal Antibodies Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Cancer Monoclonal Antibodies Market Analysis

The cancer monoclonal antibodies market is expected to witness a CAGR of 9.2% during the forecast period (2022-2027).

The COVID-19 pandemic is an unprecedented health concern that is impacting the tumor ablation market. For instance, a study titled 'Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study' in 2020 reported that A total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). In the study "Monoclonal antibodies and cancer treatment: What to know" published in November 2020, cancer isn't the only disease treated with monoclonal antibodies. Antibody targets on the coronavirus have also been identified. Monoclonal antibodies help shorten the time of severe illness by preventing the infected cells from multiplying. Thus, expanded application of monoclonal antibodies in COVID-19, the studied market had been significantly impacted by COVID-19.

Certain factors that are driving the market growth include the growing prevalence of cancer, increasing investment in R&D of genomic studies, and rising advancements in and preference toward the specificity of monoclonal antibodies to target cancer. Furthermore, the increasing cancer burden due to several factors such as population growth and aging, and the changing prevalence of certain causes of cancer are linked to social and economic development. For instance, as per the World Health Organization (WHO) in February 2022, in terms of new cases of cancer, the most common cancer in 2020 were: breast (2.26 million cases); lung (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases).

In addition, as per the 2020 statistics by GLOBOCAN 2020, an estimated 19,292,789 people were diagnosed with cancer in 2020. As per the same source mentioned above, the number of people suffering from cancer is estimated to reach 30.2 million by 2040. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.

Moreover, strategic market initiatives by market players will also lead to significant growth of the market. In February 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza agreed to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, a monoclonal antibody that binds to a cell surface target called kappa myeloma antigen (KMA) that is only found on myeloma cancer cells and not on normal plasma cells.

However, following the regulatory guidelines for monoclonal antibodies related to cancer is a highly rigorous process in most regions, globally. Thus, may impact the growth of the market over the forecast period.

Cancer Monoclonal Antibodies Industry Segmentation

As per the scope of the report, monoclonal antibodies are highly specific to cancer cells, as they bind to the proteins on their surface and stimulate an immune response. This market consists of several types of monoclonal antibodies and much more in the pipeline. The Cancer Monoclonal Antibodies Market is segmented By Types of Monoclonal Antibody (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies), By Monoclonal Antibody Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal Antibody Therapies), By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Types of Monoclonal Antibody
Murine Antibodies
Chimeric Antibodies
Humanized Antibodies
By Monoclonal Antibody Therapies
Bevacizumab (Avastin)
Rituximab (Rituxan)
Trastuzumab (Herceptin)
Cetuximab (Erbitux)
Panitumumab (Vectibix)
Other Monoclonal Antibody Therapies
By Application
Breast Cancer
Blood Cancer
Liver Cancer
Brain Cancer
Colorectal Cancer
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Cancer Monoclonal Antibodies Market Size Summary

The cancer monoclonal antibodies market is poised for significant growth, driven by the increasing prevalence of cancer and advancements in targeted therapies. The market is experiencing a robust expansion due to the rising demand for monoclonal antibodies in cancer treatment, supported by substantial investments in research and development. The growing cancer burden, influenced by factors such as population growth and aging, is further propelling market growth. The COVID-19 pandemic has also impacted the market, with monoclonal antibodies being explored for their potential applications beyond cancer, including in the treatment of COVID-19. Strategic initiatives by key market players, such as collaborations and product approvals, are expected to enhance the market's growth trajectory.

North America is a leading region in the cancer monoclonal antibodies market, benefiting from the expertise of pharmaceutical and biotechnology firms in this domain. The high incidence of cancer in the region is driving demand for monoclonal antibodies, with regulatory approvals further bolstering market expansion. The market is characterized by a high level of consolidation, with major companies like Amgen Inc., Bristol Myers Squibb Company, and F. Hoffmann-La Roche AG holding substantial market shares. The focus on developing fully-humanized monoclonal antibodies is expected to increase, given their perceived advantages in terms of immunogenicity. Overall, the market is anticipated to continue its growth trajectory, supported by ongoing innovations and strategic developments.

Explore More

Global Cancer Monoclonal Antibodies Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Prevalence of Cancer

      2. 1.2.2 Increasing Investment in Research and Development of Genomic Studies

      3. 1.2.3 Rising Advancements and Preference toward Specificity of Monoclonal Antibodies to Target Cancer

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Guidelines

      2. 1.3.2 Long Duration of Research and Development with Rising Failures in Clinical Trials

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Types of Monoclonal Antibody

      1. 2.1.1 Murine Antibodies

      2. 2.1.2 Chimeric Antibodies

      3. 2.1.3 Humanized Antibodies

    2. 2.2 By Monoclonal Antibody Therapies

      1. 2.2.1 Bevacizumab (Avastin)

      2. 2.2.2 Rituximab (Rituxan)

      3. 2.2.3 Trastuzumab (Herceptin)

      4. 2.2.4 Cetuximab (Erbitux)

      5. 2.2.5 Panitumumab (Vectibix)

      6. 2.2.6 Other Monoclonal Antibody Therapies

    3. 2.3 By Application

      1. 2.3.1 Breast Cancer

      2. 2.3.2 Blood Cancer

      3. 2.3.3 Liver Cancer

      4. 2.3.4 Brain Cancer

      5. 2.3.5 Colorectal Cancer

      6. 2.3.6 Other Applications

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Cancer Monoclonal Antibodies Market Size FAQs

The Global Cancer Monoclonal Antibodies Market is projected to register a CAGR of 9.20% during the forecast period (2024-2029)

Amgen Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd (Genentech Inc), Merck & Co., Inc and Novartis AG are the major companies operating in the Global Cancer Monoclonal Antibodies Market.

Cancer Monoclonal Antibodies Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)